New Cornell discovery could lead to effective treatment for tuberculosis

A recent discovery by Cornell University researchers could lead to a new, effective treatment for persistent tuberculosis infections.

Brian VanderVen, assistant professor of microbiology and immunology, along with colleagues at Cornell's College of Veterinary Medicine have discovered a key metabolic mechanism in Mycobacterium tuberculosis (Mtb) bacteria, which could lead to new drugs for treating tuberculosis. The findings are published in the journal eLife.

Mtb, which currently infects nearly 1.5 billion people worldwide and causes more than 1 million deaths each year, requires host lipids -- cholesterol and fatty acids -- to maintain infection. This is considered a defining characteristic of this pathogen, and is thought to support the bacterium's ability to persist for long periods of time in hosts during both latent and active infections.

The mechanisms of how Mtb assimilates the host's fatty acids has remained a mystery -- until now. Using a genetic screen, VanderVen and his team identified genes involved in cholesterol metabolism. This identified the gene LucA. To tease out what the LucA protein does, VanderVen's team created a novel LucA Mtb mutant, which revealed that the protein encoded by the gene LucA is an integral membrane protein required for fatty acid and cholesterol uptake in Mtb. Further work determined that LucA interacts with subunits of specific proteins in the Mce1 and Mce4 complexes, which import fatty acids and cholesterol, respectively. Specifically, LucA stabilizes the transporters -- acting as an integral linchpin that, if removed, causes Mce1 and Mce4 to fall apart.

"Our data highlights the complexities and weaknesses of a highly successful intracellular pathogen," said VanderVen. The discovery sheds new light on how Mtb metabolizes fatty acids and cholesterol, and also firmly establishes that LucA is required for full virulence of Mtb in vivo, and is therefore is a novel drug target in Mtb.

The next step for VanderVen and his team will be to investigate drugs that inhibit LucA. "This is ideal, because LucA is a bottleneck and inhibiting this protein with a chemical could disable two pathways at a time," said VanderVen. As it happens, "we already have discovered chemicals that do just that, so the next step will be to begin refining these as potential therapeutics."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CD4 T cells found to be key players in tuberculosis defense